Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy
- 276 Downloads
The use of intravitreal vascular endothelial growth factor (VEGF) inhibitor medications has widened considerably to include indications affecting females of reproductive age. Our patient was inadvertently exposed to bevacizumab within the first trimester when placental growth and fetal organogenesis take place and patient suffered pregnancy loss. There is insufficient information to suggest that such use is safe, nor is there definitive evidence to suggest that it causes harm. We advise that ophthalmologists discuss pregnancy with women of childbearing age undergoing intraocular anti-VEGF injections and in pregnant woman counselling is needed to explain the potential risks and benefits.
KeywordsIntravitreal vascular endothelial growth factor Pregnancy Complication
Compliance with ethical standards
Conflict of interest
Authors do not have any financial interest in the subject matter of this article.
- 5.E Rosen, A Rubowitz and J R Ferencz..Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye (2009) 23, 1479; doi: 10.1038/eye.2008.218
- 11.Sullivan L, Kelly SP, Glenn A, Williams CP, McKibbin M1.Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond). 2014 ;28(4):492–4Google Scholar
- 13.Fung AE, Rosenfeld PJ & Reichel E (2006): The international bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344–1349.Google Scholar
- 14.Wu L, Martinez-Castellanos MA, Quiroz- Mercado H et al. (2007): Twelve-month safety of intravitreal injections of bevacizumab (Avastin_): results of the pan- American collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol (in press).Google Scholar
- 15.Thorn M, Piche-Nicholas N, Stedman D, Davenport SW, Zhang N, Collinge M (2012) Bowman CJEmbryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal fc receptor (FcRn) binding. Birth Defects Res B Dev Reprod Toxicol 95(5):363–375CrossRefPubMedGoogle Scholar
- 16.Briggs GG, Freeman RK, Yaffe SJ (2011) Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Wolters Kluwer/Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar